This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Salix confirms Endo's rival buyout proposal

( March 11, 2015, 16:10 GMT | Official Statement) -- MLex Summary: Salix Pharmaceuticals confirmed Wednesday that it has received an unsolicited proposal from Endo International to acquire all of the outstanding shares of common stock of the company for a combination of 1.4607 shares of Endo common stock and $45 in cash per share of Salix common stock. The company's board will review the proposal and advise their shareholders not to take any action at this time. Salix in February agreed to be acquired by Valeant Pharmaceutical for $158 per share.Statement follows in full....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login